Lupin gets USFDA nod to market oral contraceptive

The sales of the tablet were approximately $103.6 million in the US market

Pharma major Ltd has received the final approval from the United States Food and Drugs Administration (USFDA) to market a generic version of an oral conceptive called Lutera Tablets.

The sales of the tablet were approximately $103.6 million in the US market and Lupin will begin marketing the generic version shortly, the company said.

Lupin is the fifth largest generics player in the US with a share of 5.1%. It is a significant player in the cardiovascular, diabetology, asthma and pediatric segments, holding global leadership in the anti-tuberculosis area.

image
Business Standard
177 22
Business Standard

Lupin gets USFDA nod to market oral contraceptive

The sales of the tablet were approximately $103.6 million in the US market

Viveat Susan Pinto  |  Mumbai 

Pharma major Ltd has received the final approval from the United States Food and Drugs Administration (USFDA) to market a generic version of an oral conceptive called Lutera Tablets.

The sales of the tablet were approximately $103.6 million in the US market and Lupin will begin marketing the generic version shortly, the company said.

Lupin is the fifth largest generics player in the US with a share of 5.1%. It is a significant player in the cardiovascular, diabetology, asthma and pediatric segments, holding global leadership in the anti-tuberculosis area.

RECOMMENDED FOR YOU

Lupin gets USFDA nod to market oral contraceptive

The sales of the tablet were approximately $103.6 million in the US market

Pharma major Lupin Ltd has received the final approval from the United States Food and Drugs Administration (USFDA) to market a generic version of an oral conceptive called Lutera Tablets.

Pharma major Ltd has received the final approval from the United States Food and Drugs Administration (USFDA) to market a generic version of an oral conceptive called Lutera Tablets.

The sales of the tablet were approximately $103.6 million in the US market and Lupin will begin marketing the generic version shortly, the company said.

Lupin is the fifth largest generics player in the US with a share of 5.1%. It is a significant player in the cardiovascular, diabetology, asthma and pediatric segments, holding global leadership in the anti-tuberculosis area.

image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard